Flattop Biomarker for Beta Cell Maturation Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective markers for distinguishing mature β cells from immature progenitor β cells, which hinders understanding of diabetes pathomechanisms and regeneration of de-differentiated β cells, essential for cell replacement therapy.
Innovation Solution
The use of Flattop (Fltp) as a biomarker to differentiate between mature and immature β cells, allowing for the identification of compounds that can differentiate immature progenitor β cells into mature β cells and prevent de-differentiation of mature β cells, utilizing Fltp expression levels and reporter genes for precise identification and targeting.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If current methods are used to identify β cells, then general β cell detection is possible, but differentiation between mature and immature β cells cannot be achieved
Solution Approach 1:
The patent employs fluorescent protein markers (such as GFP, RFP, or YFP) that exhibit distinct color fluorescence signals to differentiate mature β cells from immature progenitor β cells. This allows visual and quantitative distinction between cell stages through fluorescence detection, achieving precise cell differentiation without complex analytical equipment.
Solution Approach 2:
The patent introduces Fltp (Flattop) as an intermediary biomarker that specifically marks mature β cells. By using this intermediate marker system, the patent enables indirect but precise identification of mature β cell status through Fltp expression levels, resolving the contradiction between detection precision and method complexity.
2Loss of information
If no specific biomarker is used, then general β cell population can be studied, but understanding of diabetes pathomechanisms and regeneration is hindered
Solution Approach 1:
The patent extracts and isolates the Fltp biomarker signal from the complex β cell population by using fluorescently labeled antibodies or reporter genes specific to Fltp. This extraction of the maturation-specific signal enables independent analysis of mature β cells within the heterogeneous population, preventing loss of maturation information while maintaining ease of implementation through standard immunodetection or reporter assays.
3Measurement precision
If Fltp biomarker is used to distinguish mature β cells, then precise identification is achieved, but additional detection steps are required
Solution Approach 1:
The patent merges the detection of Fltp biomarker with existing β cell identification methods by using dual fluorescent labeling or combined immunofluorescence assays. This allows simultaneous detection of both β cell identity and mature status in a single experiment, maintaining high precision while improving analysis throughput by reducing separate detection steps.
Data Source
AI summary
The present invention relates to the use of the biomarker Flattop (Fltp) for distinguishing mature β cells from immature progenitor β cells. The present invention further relates to a method for distinguishing a mature β cell from an immature progenitor β cell, the method comprising: determining the presence or absence of the biomarker Flattop (Fltp) in a β cell; wherein the presence of Fltp in the cell indicates that the cell is a mature β cell and wherein the absence of Fltp in the cell indicates that the cell is an immature progenitor β cell. Furthermore, the present invention relates to a method of identifying a compound suitable for differentiating immature progenitor β cells into mature β cells as well as to a method of identifying a compound suitable for preventing the de-differentiating of mature β cells. The present invention additionally relates to a method of differentiating immature progenitor β cells into mature β cells as well as to a method of preventing de-differentiating of mature β cells. In addition, the present invention also relates to a kit for distinguishing mature β cells from immature progenitor β cells and to a pharmaceutical composition for use in treating or preventing diabetes.